Polycystic ovary syndrome as a rare association with inflammatory hepatocellular adenoma: A case report

Cazorla, Arnault; Félix, Sophie; Valmary‐Degano, Séverine; Sailley, N.; Thévenot, Thierry; Heyd, Bruno; Bioulac‐Sage, Paulette

doi:10.1016/j.clinre.2014.05.005

Cited by 3 publications

(2 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Obesity, metabolic syndrome, 20–26 vascular liver diseases (VLDs), 27–31 genetic diseases 32–43 and alcohol consumption 7 have also been identified as predisposing factors. Table 1 summarises the main risk factors, including several liver diseases associated with HCAs 44,45 . In addition, HCAs have been described in other situations, but, so far, without demonstration of a direct link, i.e.…”

Section: Risk Factorsmentioning

confidence: 99%

Hepatocellular adenoma: what we know, what we do not know, and why it matters

et al. 2022

View full text Add to dashboard Cite

Hepatocellular adenoma: what we know, what we do not know, and why it mattersIn the last two decades there has been significant progress in research on and diagnosis of hepatocellular adenoma (HCA), resulting in the establishment of a molecular and immunohistological HCA classification. This review aims to fine-tune the current expertise in order to enhance the histopathological diagnostic possibilities, by refining issues that are already known, addressing diagnostic difficulties, and identifying still unknown aspects of HCA. We discuss novel methods to identify HCA subtypes, in particular the sonic hedgehog HCAs and the interpretation of glutamine synthetase patterns for the recognition of b-cateninmutated HCAs. The major complications of HCAs, i.e. bleeding and malignant transformation, are considered, including the dilemmas of atypical and borderline lesions. HCAs in different clinical and geographical settings, e.g. pregnancy, cirrhosis and non-western countries, are also discussed. The natural history of the different HCA subtypes in relation to age, sex and risk factors is a feature that is still insufficiently investigated. This is also true for the risks of clinical bleeding and malignant transformation in association with HCA subtypes. As HCA is a relatively rare tumour, a multicentre and multidisciplinary approach across geographical boundaries will be the appropriate method to establish prospective programmes with which to identify, classify and manage HCAs, focusing on several aspects, e.g. aetiology, underlying liver disease, complications, regression, and growth. Updating what we know and identifying and addressing what we do not know matters for optimal patient management.

show abstract

Section: Risk Factorsmentioning

confidence: 99%

Hepatocellular adenoma: what we know, what we do not know, and why it matters

et al. 2022

View full text Add to dashboard Cite

show abstract

“…The observed rate of hepatic adenoma, however, is more than expected by oral contraceptive use alone in this population (Patacsil et al, 2020; Rodrigues et al, 2020). Recent examinations propose that an endogenous imbalance of sex hormones may be a risk factor (Beuers et al, 1991; Cazorla et al, 2014; Shreenath & Kahloon, 2023). Other confounding factors, which may increase the risk of hepatic adenoma in Turner Syndrome, warrant further investigation.…”

Section: Discussionmentioning

confidence: 99%

Turner syndrome may be associated with hepatic adenoma

Ching,

Zhang,

Furuya

et al. 2023

American J of Med Genetics Pt A

View full text Add to dashboard Cite

Turner syndrome, caused by complete or partial loss of an X chromosome, is marked by a range of clinical manifestations including short stature, cardiovascular and renal disease. Hepatic involvement is an increasingly recognized concern. Steatosis and elevated transaminases are commonly observed in this population, but case reports have also described hepatic adenoma. Hepatic adenomas are rare, occurring in one per million people in the general population. They are typically benign but malignant transformation or rupture can occur. We sought to investigate whether Turner syndrome is associated with hepatic adenoma. Patients with Turner syndrome encountered at a single, academic institution between 2006 and 2020 were identified using ICD‐10 codes and demographic, medication, laboratory, and imaging data were analyzed. Of the 228 patients identified, 46.9% had liver function testing, which were abnormal in 48.6%. Five of 77 patients with hepatic imaging had abnormalities. Three patients (1.3%) had hepatic adenoma, one after presenting in hemorrhagic shock due to rupture. These findings suggest that patients with Turner syndrome may have an increased risk for developing hepatic adenoma. Annual monitoring of liver function tests is already recommended in Turner syndrome. The addition of periodic hepatic imaging may also be beneficial.

show abstract

Pathological Classification and Surgical Approach to Hepatocellular Adenomas

Dokmak

2018

Primary and Metastatic Liver Tumors

View full text Add to dashboard Cite

Polycystic ovary syndrome as a rare association with inflammatory hepatocellular adenoma: A case report

Cited by 3 publications

References 20 publications

Hepatocellular adenoma: what we know, what we do not know, and why it matters

Hepatocellular adenoma: what we know, what we do not know, and why it matters

Turner syndrome may be associated with hepatic adenoma

Pathological Classification and Surgical Approach to Hepatocellular Adenomas

Contact Info

Product

Resources

About